Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma

This cohort study examines treatment with neoadjuvant-intent cemiplimab or pembrolizumab for patients with locoregionally advanced cutaneous squamous cell carcinoma in a clinical setting.
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research